Display options
Cite
Cohen S, Mehrabi S, Yao X, et al. Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma. Cancer Res J (N Y N Y). 2017;4(6):106-114doi: 10.11648/j.crj.20160406.13.
Cohen, S., Mehrabi, S., Yao, X., Millingen, S., & Aikhionbare, F. O. (2016). Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma. Cancer research journal, 4(6), 106-114. https://doi.org/10.11648/j.crj.20160406.13
Cohen, Shakeria, et al. "Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma." Cancer research journal vol. 4,6 (2016): 106-114. doi: https://doi.org/10.11648/j.crj.20160406.13
Cohen S, Mehrabi S, Yao X, Millingen S, Aikhionbare FO. Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma. Cancer Res J (N Y N Y). 2016 Nov;4(6):106-114. doi: 10.11648/j.crj.20160406.13. Epub 2017 Jan 09. PMID: 28503633; PMCID: PMC5427055.
Copy Download .nbib Format: NLM
Share it on

Cancer Res J (N Y N Y). 2016 Nov;4(6):106-114. doi: 10.11648/j.crj.20160406.13. Epub 2017 Jan 09.

Reactive Oxygen Species and Serous Epithelial Ovarian Adenocarcinoma.

Cancer research journal

Shakeria Cohen, Sharifeh Mehrabi, Xuebiao Yao, Stephanie Millingen, Felix O Aikhionbare

Affiliations

  1. Department of Internal Medicine, Morehouse School of Medicine, Atlanta, USA.
  2. Department of Physiology, Morehouse School of Medicine, Atlanta, USA.

PMID: 28503633 PMCID: PMC5427055 DOI: 10.11648/j.crj.20160406.13

Abstract

Serous ovarian cancer (SOC) is usually diagnosed at late stage and stage-adjusted five year survival rate is low. Mortality is relatively heavy on African-Americans/Black (AA) affected with SOC compared to their Caucasian counterparts, though the cause for the disparity remains unclear. DNA damage induced by oxidative stress has been linked to ovarian cancer, but the role of oxidative stress in distinguishing differences in aggressive SOC tumors among patients is yet to be determined. This study aims to determine the levels of reactive oxygen species (ROS), malondialdehyde (MDA), reactive carbonyl groups and antioxidants in primary SOC normal, precancerous (cystadenoma, borderline) and invasive (III/IV) tissue samples obtained from AA and Caucasian subgroups. Additionally, the study seeks to investigate significant changes in the level of ROS between AA and Caucasian SOC samples. A fluorogenic probe, dichlorodihydrofluorescein (DCFH-DiOxyQ), was used to scavenge reactive oxygen species in SOC normal, precancerous and malignant stages III/IV tissue samples. Malondialdehyde (MDA), a lipid peroxidation marker, and reactive carbonyl groups were measured as indicators of oxidative injury. Moreover, antioxidant status was assessed by estimating glutathione peroxidase 3 (GPX3) enzyme levels. Results indicate ROS concentration was approximately 96% higher in the malignant tissues in comparative to the normal non-diseased controls. In addition, ROS concentration among AA women was approximately 9% higher than Caucasian women. MDA levels increased exponentially from non-disease control and precancerous tissues relative to malignant tissues. Furthermore, malignant serous ovarian samples showed significantly higher reactive carbonyl content compared to the non-disease controls (p=0.009), while GPX3 levels decreased considerably in serous cystadenoma and malignant tissue samples, and non-diseased control compared to borderline disease. The results suggest accumulation of ROS and MDA levels may be a causative factor for SOC. Elevated levels of MDA and reactive carbonyl proteins could override the GPX3 enzyme capacity therefore, initiating serous ovarian neoplasm.

Keywords: Dichlorodihydrofluorescein; Glutathione Peroxidase 3; Malondialdehyde; Reactive Oxygen Species; Serous Ovarian Cancer

References

  1. Am J Epidemiol. 2009 Sep 1;170(5):598-606 - PubMed
  2. J Biol Chem. 1997 Aug 15;272(33):20313-6 - PubMed
  3. Biomed Res Int. 2014;2014:585083 - PubMed
  4. Nat Rev Cancer. 2011 Feb;11(2):85-95 - PubMed
  5. Biochem Soc Trans. 2003 Dec;31(Pt 6):1441-4 - PubMed
  6. J Carcinog. 2006 May 11;5:14 - PubMed
  7. Semin Cancer Biol. 2014 Apr;25:23-32 - PubMed
  8. Lancet. 1994 Nov 5;344(8932):1250-4 - PubMed
  9. Int J Gynecol Pathol. 1993 Apr;12(2):120-7 - PubMed
  10. Sci Transl Med. 2013 Jul 3;5(192):192ra85 - PubMed
  11. Annu Rev Plant Biol. 2004;55:373-99 - PubMed
  12. J Cancer Res Ther. 2010 Oct-Dec;6(4):487-91 - PubMed
  13. Annu Rev Plant Physiol Plant Mol Biol. 1996 Jun;47:127-158 - PubMed
  14. Arch Biochem Biophys. 1990 Mar;277(2):228-33 - PubMed
  15. Am J Surg Pathol. 2010 Mar;34(3):433-43 - PubMed
  16. Gynecol Oncol. 2014 May;133(2):353-61 - PubMed
  17. J Ovarian Res. 2009 Oct 09;2:13 - PubMed
  18. BMC Cancer. 2011 Aug 27;11:382 - PubMed
  19. Radiographics. 2005 Nov-Dec;25(6):1689-92 - PubMed
  20. FEBS Lett. 1995 Jan 16;358(1):1-3 - PubMed
  21. J Carcinog. 2007 Jan 26;6:1 - PubMed
  22. J Clin Pharm Ther. 2001 Apr;26(2):141-4 - PubMed
  23. Free Radic Res. 2000 Nov;33 Suppl:S99-108 - PubMed
  24. Clin Chem Lab Med. 2003 Oct;41(10):1281-8 - PubMed
  25. Free Radic Biol Med. 2001 Jun 1;30(11):1191-212 - PubMed
  26. J Ovarian Res. 2011 Oct 22;4:18 - PubMed
  27. Anal Biochem. 2014 Aug 1;458:69-71 - PubMed
  28. Methods Enzymol. 1999;300:145-56 - PubMed
  29. Triangle. 1973;12(4):153-8 - PubMed
  30. Lancet. 1971 Jul 17;2(7716):163 - PubMed
  31. Med Hist. 2009 Oct;53(4):489-512 - PubMed

Publication Types

Grant support